The drug Remdesivir, for which Gilead holds a patent, has been approved for sale in the EU and for use in treatment of COVID-19. This is the first product against COVID-19 to be recommended by the European Medicines Agency for conditional marketing authorization. The drug can only be used in inpatient medical facilities.